Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study

Tempest Therapeutics Inc TPST announced early results from a Phase 1b/2 study of TPST-1120 for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).